This WMass college is offering free course in AI essentials
'AI Essentials,' a real-time, instructor-led online training program will run on Tuesdays and Thursdays, June 24 to Sept. 11, from 5:45 to 8:45 p.m. each day.
The class is free for eligible Massachusett residents.
Over 12 weeks, participants will learn the fundamentals of AI, including prompt engineering, tokenization, embeddings, model structures, retrieval-augmented generation, agency, compute and ethics.
The course emphasizes practical applications, leveraging tools such Google AI Studio, n8n, and OpenWebUI to explore how AI models are built, trained, and deployed in the real world.
'Along the way, participants will gain valuable professional development experience, enhancing their technical skills and problem-solving abilities,' said Arvard Lingham, HCC executive director of community education and corporate training.
Limited seats are available. Laptops and WiFi hotspots for Internet access will be provided for students who need them.
Funding for the program comes from the Western Mass Alliance for Digital Equity.
To sign up for classes, send an email to admissions@albanycancode.org, or go to cancode.org/apply-now and choose 'AI Essentials.'
Read the original article on MassLive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Builds on clearances already received by FDA and EMA China has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) in China to proceed with a pivotal trial to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC). 'This regulatory clearance to proceed with a pivotal trial in China is a significant milestone towards reaching global markets where HCC has high prevalence,' said Sam Whiting M.D., Ph.D., chief medical officer and head of R&D of Tempest. 'It is rewarding that the regulatory officials in China see the promise and potential of amezalpat and have provided the green light to begin a registration-directed trial. We strongly believe amezalpat is a drug that can make a difference in the lives of patients with HCC and believe it should be advanced to pivotal testing.' About the TPST-1120-301 Study (NCT06680258) The planned Phase 3 study is a global, blinded, 1:1 randomized study of amezalpat plus atezolizumab and bevacizumab versus placebo plus atezolizumab and bevacizumab, the standard of care, for the first-line treatment of patients with unresectable or metastatic HCC. The company has also received agreement from the FDA and EMA on its Phase 3 study design, dose of amezalpat, and the statistical plan, including a pre-specified efficacy analysis that could shorten the time to primary analysis. About Hepatocellular Carcinoma HCC is an aggressive cancer with rising mortality and is projected to become the third leading cause of cancer death by 2030.1 Every year, more than 900,000 people worldwide are diagnosed with HCC.2 Incidence and mortality are highest in East Asia and are increasing in parts of Europe and the US.3 In the US, HCC represents the fastest-rising cause of cancer-related death.3 Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C infection, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcohol-related liver disease (ALD) and cirrhosis resulting from these conditions.4 Even if diagnosed in the early stage, an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery.5 Early recurrence is associated with poorer prognosis and shorter survival.5,6 Tumor size, number of tumors, and portal vein invasion are associated with an increased risk of recurrence.6 About Amezalpat Amezalpat is an oral, small molecule, selective PPAR⍺ antagonist. Data suggest that amezalpat treats cancer by targeting tumor cells directly and by modulating immune suppressive cells and angiogenesis in the tumor microenvironment. In an ongoing global randomized Phase 1b/2 study of amezalpat in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, the amezalpat arm showed clinical superiority across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when compared to atezolizumab and bevacizumab alone, the standard of care. These randomized data were supported by additional positive results observed in the Phase 1 clinical trial in patients with heavily pretreated advanced solid tumors, including renal cell carcinoma and cholangiocarcinoma. About Tempest Therapeutics Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the 'Securities Act')) concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'could', 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding: the design, initiation, progress, timing, scope and results of clinical trials, including the anticipated Phase 3 study for amezalpat; anticipated therapeutic benefit and regulatory development of the Company's product candidates the Company's ability to advance into a late-stage clinical company; and the Company's ability to achieve its operational plans. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Any factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the 'Risk Factors' section of the Company's Quarterly Report on Form 10-Q filed for the quarter ended March 31, 2025 and other documents filed by the Company from time to time with the Securities and Exchange Commission. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics' views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics. Investor Contacts: Sylvia WheelerWheelhouse Life Science Advisorsswheeler@ Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@ i If approved by the FDA 1 Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913-2921 (2014).2 World Health Organization. Liver Cancer Factsheet. Globocan. 2020. Available at: Last accessed: April 2023.3 Llovet, J. M., Kelley, R. K., Villanueva, A., et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021, 7(1), 6.4 Office for Health Improvement & Disparities. Liver disease profiles: November 2021 update. Available at: Last accessed: April 2023.5 Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology. 2020 May;16(15):975-989.6 Saito A, Toyoda H, Kobayashi M et al. Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Modern Pathology. 2021. 34, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
25-06-2025
- Forbes
How AI Can Help Your Kid Become An Entrepreneur Before They Graduate
How AI Can Help Your Kid Become An Entrepreneur Before They Graduate You know the thrill of a good idea. And the headache of turning that idea into something real. You've felt the friction. Finding the right tools, learning the tech (or finding someone who has), staying up late because no one else can quite see the vision like you can. That friction is where most ideas quietly die. Entrepreneurial Execution Is Getting Easier This week, I attended Google I/O Connect in Berlin, an event for the developer community. I wasn't there as a coder but as an observer of the AI developments that are rapidly reshaping our world. I got to attend a closed-door conversation with the architects of Google AI Studio. Google AI Studio is a platform that allows users to "vibe code" applications. Essentially, to create software by describing what you want it to do in plain English. While currently adept at building smaller, personal apps and prototypes, its ability to create more complex, scalable solutions is still lacking. So I asked this question: "Are we close to a future where anyone can build a robust, full-stack application without writing a single line of code?" The team's response blew me away. It was unequivocal and brimming with confidence: 'We're very close.' If tools like this really are getting easier, smarter and more powerful, the game isn't just changing for coders, it's changing for everyone. Including our kids. Why? The hardest part of launching a business has always been execution. Not the idea, but building the thing. And if that wall starts to come down? The barrier to entry shrinks. A lot. That means your child's wild idea, the one they scribbled in a notebook, or mentioned over dinner, might not need years of coding, funding or pitching to see daylight. It might just need a well-written prompt and a bit of curiosity. If execution becomes easier, other skills start to matter more. Essential Skills Every Child Should Learn Here's what I think tomorrow's entrepreneurs (including the ones you're raising) will need to thrive: In a world where AI can build the product, the person who can best explain the product wins. Think less about 'Can they code?' and more about 'Can they describe what they want to build, in detail and guide the process?' Prompting is the new prototyping. It's about structure, intent, clarity and iteration. It's knowing how to give feedback to a machine that gets better with every round. Take away the technical barrier and the next challenge is knowing what to build. The most valuable skill will be spotting opportunities others miss. Whether that's a clunky system at school, a niche community lacking tools or a global problem begging for innovation. The best builders will be the ones who ask better questions. Ones that start with, 'Why hasn't anyone fixed this yet?' Encouraging your kids to be curious and resourceful isn't a nice-to-have anymore. It's essential prep for what's next. Even if AI builds the product, it won't build the business. Your kids will still need to understand customers, cash flow and competition. They'll still need to know how to tell a story, build trust and deliver real value to people. These timeless skills aren't going anywhere. Sam Altman, the CEO of OpenAI, predicted that we'd start seeing one-person billion-dollar companies. A few years ago, that would have been laughable. Today? Feels like we're getting there fast. A Head Start In How To Think This next generation doesn't just have access to better tools, they're growing up with a different mindset. Less 'wait until someone else builds it,' and more 'what if I could?' This isn't necessarily about turning your 10-year-old into a startup founder. It's about giving them a head start in how to think. It's teaching them how to take initiative, spot problems and express their ideas clearly. The future won't belong to the people who memorized the most. It'll belong to the ones who can create, adapt and communicate. I'll leave you with this final question: does your child's education prioritize these skills?
Engadget
25-06-2025
- Engadget
Google's Imagen 4 text-to-image model promises 'significantly improved' boring images
Google has unveiled its latest text-to-image model Imagen 4 with the usual promise of "significantly improved text rendering" over the previous version, Imagen 3. The company also introduced a new deluxe version called Imagen 4 Ultra designed to follow more precise text prompts if you're willing to pay extra. Both arrive to a paid preview in the Gemini API and for limited free testing in Google AI Studio. Google describes the main Imagen 4 model as "your go-to for most tasks" with a price of $.04 per image. Imagen 4 Ultra, meanwhile, is for "when you need your images to precisely follow instructions" with the promise of "strong" output results compared to other image generators like Dall-E and Midjourney. That model boosts the price by 50 percent to $.06 per image. The company showed off a range of images including a three-panel comic generated by Imagen 4 Ultra showing a small spaceship being attacked by a giant blue... space lizard? with some sound effects like "Crunch!" and inexplicably, "Had!!" The image followed the listed prompt beat for beat and looked okay, not unlike a toon rendering from a 3D app. Another prompt read " front of a vintage travel postcard for Kyoto: iconic pagoda under cherry blossoms, snow-capped mountains in distance, clear blue sky, vibrant colors." Imagen 4 output that to a "T," albeit in a generic style lacking any charm. Another image showed a hiking couple waving from atop a rock and another, a fake "avant garde" fashion shoot. The images were definitely of good quality and followed the text prompts precisely but still looked highly machine generated. Imagen 4 is fine and does seem a mild improvement from before, but I'm not exactly wowed by it — particularly compared to the market leaders, Dall-E 3 and Midjourney 7. Plus, following an initial rush of enthusiasm, the public seems to be getting sick of AI art, with the main use case apparently being spammy ads on social media or at the bottom of articles.
